EGFR and lung adenocarcinoma: Biomarkers (e.g. estrogen receptor status in breast cancer, epidermal growth factor receptor (EGFR) status in lung adenocarcinoma, mismatch repair in colorectal cancer) are frequently reported by pathologists that do not finalize the case.